Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309479 | 1.00 | KMT2A (0.61) | KMT2APKMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30309476 | 0.86 | KMT2A (0.62) | KMT2APKMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4935554 | 0.86 | KMT2A (0.62) | KMT2APKMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30309424 | 0.86 | HRH4 (0.59) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL30309443 | 0.85 | LMNA (0.53) | KMT2APKMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30309447 | 0.85 | KMT2A (0.61) | KMT2APKMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22405638 | 0.84 | ALDH1A1 (0.60) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3427781 | 0.84 | MAPT (0.72) | KMT2ALMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL28419187 | 0.84 | KMT2A (0.60) | KMT2APKMLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL34472612 | 0.84 | HRH4 (0.57) | KMT2ALMNASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | BOLD GUIDO | 2008-12-18 | — | — | US | disclosed |
| EP-1689376-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051366-A2 | DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312192-A1 | Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases | RET, PRKDC, PRKACA | KMT2A 1081/4885PKM 491/4885LMNA 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.